Literature DB >> 20142902

Psychiatric issues in renal failure and dialysis.

A De Sousa1.   

Abstract

This article aims to bring to the fore, issues regarding the interface of psychiatry and renal failure. Depression, anxiety, suicide and delirium are common complications observed in patients with renal failure. Pharmacological management of these problems need stringent monitoring on part of the psychiatrist. This article examines the various complications that may be observed in patients with renal failure while discussing treatment approaches and also emphasizing the need for interdisciplinary team work in improving the quality of life of patients with renal failure and those on dialysis.

Entities:  

Keywords:  Dialysis; psychiatric aspects; renal failure

Year:  2008        PMID: 20142902      PMCID: PMC2813124          DOI: 10.4103/0971-4065.42337

Source DB:  PubMed          Journal:  Indian J Nephrol        ISSN: 0971-4065


Introduction

Chronic kidney disease is a multifaceted problem having both physical and psychological connotations for the patient. A multidisciplinary team effort is often needed in the management of such patients. Mental health professionals may need to collaborate with nephrologists for a holistic management of such patients. The patients suffering from renal failure often present with unusual psychological problems where treatment methods vary on an individualized basis and drug therapy is often needed in the management of such problems. Patients on dialysis are in a situation of abject dependence on a machine, a procedure and a group of qualified medical professionals for the rest of his/her life.1 No other medical condition has such a degree of dependence for the maintenance treatment of a chronic illness.2 Dialysis as a procedure is stressful for the patient in the event of inadequate education and preparation with regard to pre-end-stage renal disease (ESRD). There is also a considerable restraint on the selection of foods and fluids. Patients on peritoneal dialysis have some latitude regarding this compared to patients on hemodialysis. Patients with renal failure often suffer from many other medical conditions and are on many different medications. Many of these medications may at times cause psychiatric symptoms and it is worth noting the same to avoid confusion [Table 1]. Sometimes agitation and confusion may be noted as a result of nonpsychiatric medication. These are very perplexing symptoms since the same may be observed in medical conditions such as electrolyte disturbances, hypertension, hypoglycemia, aluminum toxicity, dialysis dementia and may also be a part of depression and anxiety.3
Table 1

Selected drugs associated with neuropsychiatric morbidity and their implications on patients with renal failure

DrugSymptomsAccumulation in ESRD
Amantadine13Agitation, anxiety, confusion, depression, hallucinations and insomniaYes
Aspirin14Anxiety, insomnia, confusion, psychosisNo
Ciprofloxacin15Agitation, psychosisYes
Diphenhydramine16Confusion, anxiety, sedationProbable
Interferon17Confusion, psychosis depression, fatigue, suicidal tendencies, irritabilityNot studied
Pentazocine18Confusion, hallucinationsYes
Phenytoin19Confusion, dizziness, drowsiness, insomniaYes
Prednisolone20Anxiety, insomnia, psychosisNo
Selected drugs associated with neuropsychiatric morbidity and their implications on patients with renal failure

Depression

The most common psychiatric complication occurring as a result of renal failure is depression in the patient and anxiety in the associated partner.35 Most dialysis patients who are employed may seldom return to full time work activity. Work in addition to a source of income is often associated with a sense of accomplishment, self-esteem and identity in most patients. The current accepted psychiatric treatment for depression would include an antidepressant therapy combined with psychotherapy. Special considerations are needed while putting ESRD patients on antidepressant therapy. Presently, a wide variety of antidepressant drugs are available for the management of depression. Each of these may have varied effects on renal function, although most are safe in a large number of cases. Comparative doses of these drugs in normal adults and in those with renal failure, including their pharmacological class and side effects, have been reported [Table 2]. No studies so far have compared depression in patients with hemodialysis and continuous ambulatory peritoneal dialysis (CAPD); however, reviews with regard to the occurrence of depression in renal failure patients clearly mention that patients on CAPD experience milder symptoms.3
Table 2

Antidepressant drugs and renal function

DrugNormal adult doseDose in renal failureComment
Selective serotonin reuptake inhibitors (SSRIs)
 Citalopram2120-60 mg10-60 mgVery safe. Fluoxetine may cause loss of appetite at times and insomnia as a side effect
 Escitalopram2210-20 mg5-20 mg
 Fluoxetine2320-60 mg20-40 mg
 Fluvoxamine2450-300 mg50-300 mg
 Sertraline2550-150 mg50-150 mg
 Paroxetine2620-60 mg10-30 mgDose should be reduced in renal failure May cause seizures at high doses
Tricyclic antidepressants
 Amitryptiline2725-75 mg25-75 mgSafe but side effects like constipation, dry mouth, blurred vision. Trazadone may cause priapism at high doses
 Imipramine2725-75 mg25-75 mg
 Doxepin2825-75 mg25-75 mg
 Amoxapine2775-200 mg75-200 mg
 Nortryptiline2725-75 mg25-75 mg
 Trazadone29150-400 mg150-300 mg
Newer antidepressants
 Venlafaxine3037.5-225 mg37.5-225 mgMay increase BP at high doses
 Mirtazapine3115-45 mg7.5-30 mgSedation common
 Duloxetine3210-80 mg10-80 mgSafe
Antidepressant drugs and renal function

Suicidal Behavior

Discussing depression further brings up the subject of suicidal behavior in dialysis and renal failure patients. Repeated observational studies have demonstrated that dialysis patients have higher suicide rates than the normal healthy population.6 It is noteworthy that when depressed, the dialysis patient has at his disposal a very effective method of escape i.e. suicide. Simply missing dialysis for some sessions or going on a potassium food binge can produce death. Moreover, under consideration in case of suicide would be the voluntary withdrawal from dialysis and ethical issues involved in it, which are beyond the scope of this article.

Delirium

Delirium is a common phenomenon observed in dialysis patients due to electrolyte imbalances that may occur after a dialysis run termed as the dialysis disequilibrium syndrome or as a consequence of medical or surgical complications.7 The causes may include uremia, anemia and hyperparathyroidism. In any aging population having diabetes and receiving dialysis, dementia may occur due to Alzheimer's disease, vascular causes and dialysis dementia syndrome. The latter is a progressive disorder and is often fatal. In all cases, the management would be on a case-by-case basis and early diagnosis and detection is a must. Ameliorative medications such as antipsychotics, lorazepam and neurotropics may be useful in these conditions. Information regarding their use in renal failure patients is sparse, and the drug of choice is often the result of past successful experiences. A list of these drugs and their normal doses along with dose restrictions in patients with renal failure has been provided [Tables 3 and 4].
Table 3

Drugs used in delirium in renal failure

DrugDose in normal adultsDose in renal failureComments
Haloperidol345-15 mg5-15 mgMay increase QT interval
Clozapine3525-400 mgTitrate dose as neededMay cause seizures above at 400 mg Agranulocytosis is common
Olanzapine365-20 mg5-20 mgSafe
Quetiapine37150-600 mg150-600 mg-
Risperidone381-4 mg0.5-2 mgSedation
Ziprasidone3720-80 mg20-80 mgMay increase QT interval
Piracetam800-4800 mg800-4800 mgSafe
Table 4

Anti-anxiety drugs and renal failure

DrugDose in normal adults (mg/day)Dose in renal failure (mg/day)Comment
Alprazolam380.25-4 mg0.25-2 mgEffective in the management of anxiety and insomnia. May cause drowsiness at high doses that may be confused with delirium
Clonazepam390.5-1.5 mg0.5-1.5 mg
Lorazepam391-4 mg1-4 mg
Diazepam405-40 mg5-25 mg
Buspirone415-20 mg5-20 mgSafe anti-anxiety drug. No sedation
Zolpidem425-20 mg HS5-20 mg HSShort-acting drugs and no residual drowsiness
Zaleplon425-10 mg HS5-10 mg HS
Drugs used in delirium in renal failure Anti-anxiety drugs and renal failure

Anxiety and Panic Symptoms

Extreme anxiety and anxiety somatic symptoms such as breathlessness, palpitations, chest pain, sweating and fear of dying may occur in renal failure cases. Many a times, these symptoms are not associated with any triggers and may occur unexpectedly. There are, on the other hand, many reasons regarding the occurrence of anxiety. The process of dialysis and a multitude of potential medical complications give the patient a lot to worry and anticipate about. Pharmacological management is paramount in the management of anxiety and panic. Benzodiazepines such as clonazepam and alprazolam may be used to reduce anxiety in such patients. Many patients with anxiety also tend to experience insomnia. Drugs such as zolpidem and zaleplon are useful in the management of such insomnias with no residual drowsiness and minimal side effects. Doses of some of these drugs may have to be adjusted to suit the needs of the nephrologically compromised patient [Table 4]. One must be careful with benzodiazepines as a group as they tend to cause sedation at higher doses which may be mistaken for other delirious conditions.

Problems in Receiving Psychiatric Help

Renal failure patients have been noted as the biggest deniers of psychiatric illness.1 They often feel that they are overdoctored and even motivational psychotherapy is best administered in the dialysis unit itself. Many patients on dialysis do well if individual psychotherapy is administered during the dialysis sessions itself. Another complication is the nonadherence to the treatment and medical regimens. Such patients take appointments, but do not visit the doctor and may also get angry on the staff of the dialysis unit. The dialysis population is not just a cross section of the general population. This group is skewed in the direction of the noncompliant diabetic, noncompliant hypertensive and also the alcoholic. These patients often express their anger as they feel that many others lead a normal life, while they have to suffer and undergo repeated medical procedures. Professional staff members handling dialysis patients are high achievers in life educationally and professionally. They often have the tendency to identify with patients and project their values regarding dialysis on the patients regarding what they would do if they had renal failure and had to undergo dialysis. This is a common fallacy and needs to be kept in mind while setting realistic goals for these people. The staff members must be strict while handling patients, although gentle when needed. The average age of the ESRD patient is 65 years. They are not only older but more infirm.8–9 Many of them have comorbid diabetes, hypertension, peripheral arterial disease, cardiomyopathies and arthropathies, which contribute to patient symptoms and reduction in the quality of life (QOL).10ȓ11 Denial of death is also a common problem in such patients. Mental health professionals may often be needed in such cases to provide end-stage counseling and psychotherapy.12 An increase has been projected in ESRD patients worldwide with decrease in the number of nephrologists, specialized staff and professionals trained to help them. An effective team work often, interdisciplinary, is a must in the effective management of interconnected problems; it is only the collaborative effort that leads to better outcomes and improved quality of life.41
  39 in total

1.  "Springing back" advance care planning in dialysis.

Authors: 
Journal:  Am J Kidney Dis       Date:  1999-05       Impact factor: 8.860

Review 2.  Drug-induced psychosis and depression in the elderly.

Authors:  K A Wood; M J Harris; A Morreale; A L Rizos
Journal:  Psychiatr Clin North Am       Date:  1988-03

3.  Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis.

Authors:  O Spigset; S Hägg; B Stegmayr; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of mirtazapine.

Authors:  C J Timmer; J M Sitsen; L P Delbressine
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

Review 5.  Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-03       Impact factor: 9.546

6.  Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study.

Authors:  S Greenstein; B Siegal
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

7.  Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.

Authors:  E Tiula; L G Tallgren; P J Neuvonen
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-10

8.  Diazepam kinetics in patients with renal insufficiency or hyperthyroidism.

Authors:  H R Ochs; D J Greenblatt; H J Kaschell; U Klehr; M Divoll; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of fluvoxamine.

Authors:  E Perucca; G Gatti; E Spina
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

10.  The pharmacokinetics of risperidone in humans: a summary.

Authors:  J Heykants; M L Huang; G Mannens; W Meuldermans; E Snoeck; L Van Beijsterveldt; A Van Peer; R Woestenborghs
Journal:  J Clin Psychiatry       Date:  1994-05       Impact factor: 4.384

View more
  13 in total

1.  Anxiety, depression and suicidal ideation in Lebanese patients undergoing hemodialysis.

Authors:  Gabrielle Macaron; Mario Fahed; Dany Matar; Rami Bou-Khalil; Francois Kazour; Dania Nehme-Chlela; Sami Richa
Journal:  Community Ment Health J       Date:  2013-12-13

2.  Prevalence of Mental Disorders in a German Kidney Transplant Population: Results of a KTx360°-Substudy.

Authors:  Katrin Birkefeld; Maximilian Bauer-Hohmann; Felix Klewitz; Eva-Marie Kyaw Tha Tun; Uwe Tegtbur; Lars Pape; Lena Schiffer; Mario Schiffer; Martina de Zwaan; Mariel Nöhre
Journal:  J Clin Psychol Med Settings       Date:  2022-02-23

Review 3.  The Effectiveness of Depression Treatment for Adults with ESKD: A Systematic Review.

Authors:  Pavan Chopra; Chelsea K Ayers; Jennifer R Antick; Devan Kansagara; Karli Kondo
Journal:  Kidney360       Date:  2021-01-07

Review 4.  Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.

Authors:  Abhijit Jagdale; David K C Cooper; Hayato Iwase; Robert S Gaston
Journal:  Xenotransplantation       Date:  2018-11-20       Impact factor: 3.907

5.  Associated factors for depressive disorder in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis.

Authors:  Patrinee Traisathit; Kasiramart Moolkham; Narong Maneeton; Natthapat Thongsak; Benchalak Maneeton
Journal:  Ther Clin Risk Manag       Date:  2019-04-01       Impact factor: 2.423

6.  Anxiety, locus of control, and coping strategies among end-stage renal disease patients undergoing maintenance hemodialysis.

Authors:  S Kohli; P Batra; H K Aggarwal
Journal:  Indian J Nephrol       Date:  2011-07

7.  An overview of Indian research in depression.

Authors:  Sandeep Grover; Alakananda Dutt; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

8.  Health-related Quality of Life and Existential Concerns Among Patients with End-stage Renal Disease.

Authors:  Samir Bele; Trupti N Bodhare; Nikhil Mudgalkar; Abhay Saraf; Sameer Valsangkar
Journal:  Indian J Palliat Care       Date:  2012-05

9.  Effect of Psycho Education on Depression and Anxiety Symptoms in Patients on Hemodialysis.

Authors:  Fatemeh Espahbodi; Hamzeh Hosseini; Mohamad Mehdi Mirzade; Arefeh Beygom Shafaat
Journal:  Iran J Psychiatry Behav Sci       Date:  2015-01-10

10.  Screening for depression in hospitalized pediatric patients.

Authors:  Mohammad-Reza Esmaeeli; Reza Erfani Sayar; Ali Saghebi; Saghi Elmi; Shagheyegh Rahmani; Sam Elmi; Akram Rabbani Javadi
Journal:  Iran J Child Neurol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.